Research
Hormonal
Prophylactic administration of uPAR-targeting CAR T cells in young mice prevents the development of age-related metabolic dysfunction and maintains exercise capacity into old age.
Treating young organisms with senolytic CAR T cells can prevent metabolic decline and maintain physical fitness into old age. This suggests that early intervention might be more effective than late-stage treatment.
GoodSupportsHIGH confidence
As was observed in aged animals upon therapeutic treatment, prophylactic uPAR CAR T cell administration in young mice limited metabolic decline in old age. Specifically, uPAR CAR T cell-treated mice had significantly lower fasting glucose levels, improved glucose tolerance, and enhanced pancreatic beta cell function... than mice treated with either UT or h.19-m.28z.
Why this rating
Long-term monitoring (up to 15 months) in a controlled animal model.
Source
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction
Corina Amor et al. · Nature Aging · 2024
DOI 10.1038/s43587-023-00560-5
mechanism_onlyCited 177×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- A single administration of senolytic CAR T cells targeting uPAR eliminates senescent cells in aged mice, resulting in improved glucose tolerance, reduced fasting glucose, and enhanced exercise capacity.Good
- uPAR-targeting CAR T cells effectively treat metabolic syndrome induced by a high-fat diet in young mice, improving body weight, glucose tolerance, and insulin sensitivity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →